摘要:
Provided herein are methods of treating a cancer comprising administering an EGFR degrader to a patient suffering therefrom and subjecting the patient to radiation. The cancer can express mutant, overexpressed or overly activated EGFR, mutant KRAS, or mutant BRAF.
摘要:
Disclosed are methods of treating cancer characterized by expression of at least one KRAS mutation, using a compound of Formula I, below, or a pharmaceutically acceptable salt thereof, or a prodrug thereof: (I) Also disclosed are methods of altering the level of KRAS or cMet in a cell characterized by expression of at least a KRAS mutation with the compound of Formula I.
摘要:
Provided herein are compounds that inhibit a binding interaction between an epidermal growth factor receptor (EGFR) and a heat shock protein 90 (HSP90), as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of increasing degradation of an EGFR, methods of treating cancer, and methods of sensitizing tumors to radiation therapy.
摘要:
Provided herein are processes for synthesizing compounds useful as EGFR modulators. In particular, provided herein are processes for synthesizing Compound A: